Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Evidence lacking for ’inflatable-pants’ heart failure therapy

23.02.2006


A new review of studies supports the government’s opinion that too little evidence exists to support a device that uses balloon-like pants as a treatment for heart failure.



External counterpulsation (ECP), a noninvasive therapy to improve blood flow to the heart, is most commonly used to relieve hard-to-treat chest pain for heart patients who are not candidates for surgery.

Last year, the equipment manufacturer asked the federal government to expand its coverage of ECP and begin reimbursing cardiologists who use the device for other heart conditions, including heart failure.


The Centers for Medicare and Medicaid Services -- which sets reimbursement guidelines for the two federal benefit programs -- declined to expand its policy on external counterpulsation to cover heart failure or other cardiac conditions. Now, the Technology Evaluation Center of the Blue Cross and Blue Shield Association, whose member companies represent the largest health benefits provider in the United States, has reviewed the science behind ECP for heart failure.

"The evidence supporting the role of ECP as an effective treatment for heart failure is lacking in both quantity and quality," the review found.

The one controlled trial of external counterpulsation for heart failure is unpublished. It showed some modest improvements in the time patients were able to exercise and some gains in patients’ ranking on a scale that classifies the extent of heart failure, the review said.

"To me it’s not convincing evidence," said senior scientist David Mark, M.D., of Blue Cross and Blue Shield Association’s Technology Evaluation Center.

The systematic review was conducted by the Technology Evaluation Center (TEC), which analyzes clinical and scientific evidence to evaluate whether a technology improves health outcomes. This is the first time TEC evaluated the device as therapy for heart failure, and ECP did not measure up.

TEC Assessments provide objective information to those who deliver and manage medical care. They are based on clinical and scientific evidence and evaluate whether a technology improves health outcomes, such as length of life, quality of life and ability to function. TEC Assessments are not recommendations for health care by providers or for coverage decision by health insurance companies.

Vasomedical Inc., which makes ECP technology, disagrees with the Blue Cross and Blue Shield Association opinion. In a written response, the company said external counterpulsation is a "safe, noninvasive, low-cost" therapy that could benefit many more patients.

"We are not sure where the Blue Cross and Blue Shield technology assessment group sets the threshold for clinical evidence of efficacy, but we feel strongly that we have met any reasonable standard," the statement said.

In ECP, patients wear a set of balloon-like pants programmed to inflate in sequence with the heart beat. Pneumatic cuffs fit snugly around the legs and thighs and are designed to force oxygen-rich blood to the top half of the body to fuel the heart. "The theory is that it allows the heart to rest and renew itself," said Brent O’Connell, M.D., a member of the Association’s Medical Advisory Panel, which oversaw the TEC research review.

The new review also revisits Blue Cross and Blue Shield Association’s past evaluation of ECP for chest pain, or angina. While most Blue Cross and Blue Shield companies do not cover ECP therapy for chest pain, Medicare and some other health insurers do.

Mark said that, given the measures used, rigorous studies on ECP showed a lack of consistent improvement, leaving doubts about whether even the positive findings were clinically or functionally meaningful. There is one published, randomized, controlled trial of ECP for chest pain.

Cardiologist Frederick Masoudi, with the Denver Health Medical Center, who was not involved with the new review, said while noninvasive therapies for cardiac conditions are welcome, ECP is not widely prescribed for chest pain, and is rarer as a heart failure therapy.

Masoudi said ECP is not used at any of the facilities where he works, and he has not seen patient demand for the therapy. ECP is typically administered outside of the hospital, often at freestanding care sites dedicated to the therapy.

"When this first came out, there were some major institutions who invested lots of money putting in the equipment," O’Connell said. "There’s always going to be early adopters for new technology. Most of medicine wanted to wait for the long term studies."

The 38 Blue Cross and Blue Shield health plans make independent decisions about medical coverage, and currently several plans do pay for ECP therapy. But O’Connell, who is also vice-president and medical director, Pennsylvania Blue Shield/Highmark, predicts that the TEC review will prompt some insurers to scale back coverage or change their policies in coming months.

"This is a no-brainer for those in the reimbursement field," he said.

Maxine Gere | EurekAlert!
Further information:
http://www.bcbs.com/tec/vol20/20_12.html
http://www.cfah.org

More articles from Studies and Analyses:

nachricht New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg

nachricht Disarray in the brain
18.12.2017 | Universität zu Lübeck

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Optical Nanoscope Allows Imaging of Quantum Dots

Physicists have developed a technique based on optical microscopy that can be used to create images of atoms on the nanoscale. In particular, the new method allows the imaging of quantum dots in a semiconductor chip. Together with colleagues from the University of Bochum, scientists from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute reported the findings in the journal Nature Photonics.

Microscopes allow us to see structures that are otherwise invisible to the human eye. However, conventional optical microscopes cannot be used to image...

Im Focus: Artificial agent designs quantum experiments

On the way to an intelligent laboratory, physicists from Innsbruck and Vienna present an artificial agent that autonomously designs quantum experiments. In initial experiments, the system has independently (re)discovered experimental techniques that are nowadays standard in modern quantum optical laboratories. This shows how machines could play a more creative role in research in the future.

We carry smartphones in our pockets, the streets are dotted with semi-autonomous cars, but in the research laboratory experiments are still being designed by...

Im Focus: Scientists decipher key principle behind reaction of metalloenzymes

So-called pre-distorted states accelerate photochemical reactions too

What enables electrons to be transferred swiftly, for example during photosynthesis? An interdisciplinary team of researchers has worked out the details of how...

Im Focus: The first precise measurement of a single molecule's effective charge

For the first time, scientists have precisely measured the effective electrical charge of a single molecule in solution. This fundamental insight of an SNSF Professor could also pave the way for future medical diagnostics.

Electrical charge is one of the key properties that allows molecules to interact. Life itself depends on this phenomenon: many biological processes involve...

Im Focus: Paradigm shift in Paris: Encouraging an holistic view of laser machining

At the JEC World Composite Show in Paris in March 2018, the Fraunhofer Institute for Laser Technology ILT will be focusing on the latest trends and innovations in laser machining of composites. Among other things, researchers at the booth shared with the Aachen Center for Integrative Lightweight Production (AZL) will demonstrate how lasers can be used for joining, structuring, cutting and drilling composite materials.

No other industry has attracted as much public attention to composite materials as the automotive industry, which along with the aerospace industry is a driver...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

10th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Münster, 10-11 April 2018

08.01.2018 | Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

 
Latest News

Rutgers scientists discover 'Legos of life'

23.01.2018 | Life Sciences

Seabed mining could destroy ecosystems

23.01.2018 | Earth Sciences

Transportable laser

23.01.2018 | Physics and Astronomy

VideoLinks Science & Research
Overview of more VideoLinks >>>